Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2020

Open Access 01.12.2020 | Research article

Predicting the occurrence of venous thromboembolism: construction and verification of risk warning model

verfasst von: Chen Shen, Binqian Ge, Xiaoqin Liu, Hao Chen, Yi Qin, Hongwu Shen

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2020

Abstract

Background

The onset of venous thromboembolism is insidious and the prognosis is poor. In this study, we aimed to construct a VTE risk warning model and testified its clinical application value.

Methods

Preliminary construction of the VTE risk warning model was carried out according to the independent risk warning indicators of VTE screened by Logistic regression analysis. The truncated value of screening VTE was obtained and the model was evaluated. ROC curve analysis was used to compare the test of Caprini risk assessment scale and VTE risk warning model. The cut-off value of the VTE risk warning model was used to evaluate the test effectiveness of the model for VTE patients with validation data set.

Results

The VTE risk warning model is p = ex / (1+ ex), x = − 4.840 + 2.557 • X10(1) + 1.432 • X14(1) + 2.977 • X15(1) + 3.445 • X18(1) + 1.086 • X25(1) + 0.249 • X34 + 0.282 • X41. ROC curve results show that: AUC (95%CI), cutoff value, sensitivity, specificity, accuracy, Youden index, Caprini risk assessment scale is 0.596 (0.552, 0.638), 5, 26.07, 96.50, 61.3%, 0.226, VTE risk warning model is 0.960 (0.940, 0.976), 0.438, 92.61, 91.83, 92.2%, 0.844, respectively, with statistically significant differences (Z = 14.521, P < 0.0001). The accuracy and Youden index of VTE screening using VTE risk warning model were 81.8 and 62.5%, respectively.

Conclusions

VTE risk warning model had high accuracy in predicting VTE occurrence in hospitalized patients. Its test performance was better than Caprini risk assessment scale. It also had high test performance in external population.
Begleitmaterial
Hinweise
Chen Shen and Binqian Ge contributed equally to this work.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12872-020-01519-9.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
VTE
Venous thromboembolism
ROC
Receiver operating characteristic
AUC
Area under curve
DVT
Deep venous thrombosis
PE
Pulmonary embolism
AHA
American heart association
PTS
Post-thrombotic syndrome
AT
Anticoagulant proteins
BMI
Body mass index
TP
True positive
FP
False positive
FN
False negative
TN
True negative
Acc
Accuracy
Sen
Sensitivity
PR
True positive rate
FNR
False negative rate
Spe
Specificity
TNR
True negative rate
FPR
False positive rate
LR
Likelihood ratio

Background

Venous thromboembolism (VTE) is a common disease with high morbidity and mortality [1], including deep vein thrombosis (DVT) and pulmonary embolism (PE), VTE is the third most common cardiovascular disorder. The incidence of VTE is concealed and its prognosis is poor. At the same time, the increasing incidence rate showed a trend of younger patients [2, 3]. We should focus not only on the many influencing factors of VTE [48], but also on its early identification and early intervention [9, 10]. Studies have shown a lack of clinical VTE care standards for inpatients and the low VTE prevention rate which indicate that further improvement is needed [11]. Approximately 50% of VTEs are provoked by immobilization, trauma, surgery, or hospitalization in previous 3 months [1215], and 20% associated with cancer while 30% unprovoked [1618]. VTE has many risk factors which are constantly multiplied [1925]. Currently, Caprini Risk Assessment Scale is widely used in clinical practice. However, genetic and environmental differences between Western and China limit the validity of Caprini Risk Assessment Scale in Chinese patients. Medical records which contain rich information about disease progression, are useful in mining new risk factors related to VTE patients. Each patient will undergo a series of laboratory tests upon admission, and the blood test indicators of VTE patients will be abnormal in varying degrees [2628]. The timely detection of abnormal change will facilitate the VTE occurrence risk assessment and enable early warning and intervention. Therefore, based on characteristics of VTE patients in China, this study screened out VTE risk early warning indicators other than the traditional scale, and established a VTE Risk Warning Model. This study was to effectively achieve the primary prevention of VTE and provide a scientific theory for VTE prevention.

Methods

Study population

The study conducted from January 1, 2017 to June 30, 2018 in Affiliated Hospital of Nantong University. The inclusion criteria were as follows: patients diagnosed with VTE during hospitalization, age ≥ 18 years, hospitalization time ≥ 2 days (48 h), and clinical medical records completed. Patients who had VTE before admission, those with superficial vein thrombosis, and those who used anticoagulants were excluded. Finally, we included 257 VTE patients. Two hundred fifty-seven age- and disease-duration- matched non-VTE patients of the same period were also included in this study and built the modeling data set. In addition, 63 VTE patients and 85 non-VTE patients from July 1, 2018 to December 31, 2018, were selected for a validation data set, identical inclusion criteria with the former modeling data set. This clinical research protocol complies with relevant provisions of Helsinki Declaration on the protection of the rights and interests of subjects.

Study design

The modeling data set was analyzed by T / χ2 test and Logistic regression analysis. According to VTE independent risk factors screened by Logistic regression analysis, a VTE risk warning model was constructed, and the cut-off value of VTE screening obtained. The cut-off value of VTE risk warning model was used to verify the screening efficacy of VTE risk warning model for VTE patients in the validation data set.

Assessments

Since Logistic regression using maximum likelihood estimation (MLE) method for regression coefficient estimation is sensitive to multicollinearity, a high degree of multicollinearity will lead to a great change in coefficient estimation value or symbol. Therefore, multicollinearity analysis needed to be carried out before multivariate analysis. The variance expansion coefficient (VIF) diagnostic method is one of the common methods. Generally, VIF > 5 indicates multicollinearity existence. In a large sample, VIF > 10.
The Gold Standard is required in Diagnose Test to distinguish the experimental group and control group. The effectiveness of VTE risk early warning model was evaluated by four-division table of diagnostic data. The evaluation indicators mainly include Sensitivity (Sen), Specificity (Spe), Accuracy (Acc), and Youden Index (Youden’ s Index). Receiver operating characteristic curve (ROC) is a widely accepted criterion. The area under curve (AUC) below 0.6 means low discrimination, 0.6 to 0.75 medium discrimination, and above 0.75 high discrimination. The high AUC represents high model accuracy.

Statistical analysis

Statistical analysis adopted SPSS 20.0. In univariate analysis, all statistical variables of VTE group were compared with corresponding variables of control group in order to determine the P value of all statistical variables. Measurement data were described by (X ± S), and count data by frequency. The categorical variables were tested by χ2 test. The calibration was performed byχ2 test or Fisher exact probability method. And continuous variables were tested by t test or t2 test. Logistic regression was used in multivariate analysis. In this model, the variables were selected based on the results of univariate analysis. Variables in univariate analysis that were hypothesis-tested P < 0.3 (in order to prevent missing possible early warning indicators) and consistent with previous documents and clinical experience were included in the follow-up multivariate analysis. In order to simplify the model, stepwise regression method was adopted to screen model variables. The regression method was set as “Forward: LR”, and test level α = 0.05 was specified for introducing variables into the model and 0.10 for removing variables from the model. Logistic regression was used to obtain the regression coefficient, standard error, chi-square value of Wald, P value, corresponding OR value and 95% confidence interval of the possible predictors. The independent risk warning index of VTE screened by Logistic regression analysis was used to construct the VTE risk warning model, and its screening efficiency was evaluated and compared by ROC. External validation of VTE risk warning model was carried out by using the four-division of diagnostic data to evaluate its test effectiveness. P < 0.05 was considered statistically significant.

Results

Univariate analysis of VTE risk warning indicators

According to relevant literature and clinical practice, the VTE risk warning indicators which are not included in Caprini score scale mainly include four parts as following: (1) General indicators, including gender, patient origin, nationality, payment methods, length of stay (days); (2) Related indicators of current medical history, including 17 variables such as cough, expectoration, hemoptysis, dyspnea, pleural chest pain, cyanosis, pain in the precardiac area, palpitations, shortness of breath after exertion, chest tightness and shortness of breath, syncope with unknown cause, pleural effusion, unilateral lower limb Pain, deep venous tenderness in the lower limbs, pigmentation in the lower limbs, walking fatigue in the lower limbs, and increased local skin temperature in the lower limbs; (3) Relevant indicators of previous history, mainly including 7 variables such as hypertension, diabetes, smoking, systemic connective tissue disease, renal insufficiency, liver disease (hepatitis or liver damage), anemia; (4) The relevant indexes of the laboratory inspection items, mainly including 11 variables such as prothrombin time (PT), thrombin time (TT), activated partial thrombin time (APTT), Fibrinogen (FIB), Fibrinogen Degradation Product (FDP), International Normalized Ratio (INR), D-Dimerization, Albumin, platelet count, white blood cell count, number of red blood cells. In addition, we took the Caprini score as a risk warning indicator in the univariate analysis. The detailed results are shown in Table 1.
Table 1
Single factor analysis of VTE risk warning indicators in modeling dataset
Variables
No.
 
VTE group
Control group
χ2or t
P
n(%)orX ± S
n(%)orX ± S
Gender
X1
Male
109 (42.4)
123 (47.9)
1.540
0.215
Female
148 (57.6)
134 (52.1)
Patient source
X2
City
142 (55.3)
162 (63.0)
3.221
0.073
Countryside
115 (44.7)
95 (37.0)
Native place
X3
Native
249 (96.9)
253 (98.4)
1.365
0.243
Non-native
8 (3.1)
4 (1.6)
Payment method
X4
Health Insurance
111 (43.2)
138 (53.7)
5.679
0.017*
Self-paying
146 (56.8)
119 (46.3)
Length of stay (days)
X5
 
13.28 ± 6.64
13.00 ± 19.96
−2.998
0.003*
Cough
X6
No
218 (84.8)
197 (76.7)
5.517
0.019*
Yes
39 (15.2)
60 (23.3)
Expectorant
X7
No
227 (88.3)
246 (95.7)
9.568
0.002*
Yes
30 (11.7)
11 (4.3)
Hemoptysis
X8
No
244 (94.9)
251 (97.7)
2.678
0.102
Yes
13 (5.1)
6 (2.3)
Difficulty breathing
X9
No
250 (97.3)
253 (98.4)
0.836
0.361
Yes
7 (2.7)
4 (1.6)
Pleural chest pain
X10
No
230 (89.5)
251 (97.7)
14.28
<0.001*
Yes
27 (10.5)
6 (2.3)
Cyanosis
X11
No
244 (94.9)
254 (98.8)
6.451
0.011*
Yes
13 (5.1)
3 (1.2)
Anterior cardiac pain
X12
No
250 (97.3)
255 (99.2)
1.809
0.176
Yes
7 (2.7)
2 (0.8)
Palpitations
X13
No
251 (97.7)
252 (98.1)
0.093
0.761
Yes
6 (2.3)
5 (1.9)
Shortness of breath after exertion
X14
No
245 (95.3)
252 (98.1)
2.981
0.084
Yes
12 (4.7)
5 (1.9)
Chest tightness and shortness of breath
X15
No
184 (71.6)
244 (94.9)
50.272
<0.001*
Yes
73 (28.4)
13 (5.1)
Unexplained syncope
X16
No
238 (92.6)
254 (98.8)
12.157
<0.001*
Yes
19 (7.4)
3 (1.2)
Pleural effusion
X17
No
241 (93.8)
247 (96.1)
1.458
0.227
Yes
16 (6.2)
10 (3.9)
Unilateral lower limb pain
X18
No
201 (78.2)
255 (99.2)
56.671
<0.001*
Yes
56 (21.8)
2 (0.8)
Deep vein tenderness in lower limbs
X19
No
253 (98.4)
256 (99.6)
0.808
0.369
Yes
4 (1.6)
1 (0.4)
Lower extremity pigmentation
X20
No
255 (99.2)
257 (100)
0.502
0.479
Yes
2 (0.8)
0 (0)
Lower limb walking fatigue
X21
No
256 (99.6)
254 (98.8)
0.252
0.616
Yes
1 (0.4)
3 (1.2)
Local lower skin temperature increase
X22
No
252 (98.1)
256 (99.6)
1.518
0.218
Yes
5 (1.9)
1 (0.4)
Hypertension
X23
No
169 (65.8)
197 (76.7)
7.439
0.006*
Yes
88 (34.2)
60 (23.3)
Diabetes
X24
No
231 (89.9)
240 (93.4)
2.056
0.152
Yes
26 (10.1)
17 (6.6)
Smoking
X25
No
200 (77.8)
217 (84.4)
3.672
0.055
Yes
57 (22.2)
40 (15.6)
Systemic connective tissue disease
X26
No
255 (99.2)
252 (98.1)
0.579
0.447
Yes
2 (0.8)
5 (1.9)
Renal insufficiency
X27
No
248 (96.5)
254 (98.8)
3.072
0.08
Yes
9 (3.5)
3 (1.2)
Liver disease
X28
No
234 (91.1)
220 (85.6)
2.641
0.104
Yes
23 (8.9)
37 (14.4)
anemia
X29
No
246 (95.7)
250 (97.3)
0.921
0.337
Yes
11 (4.3)
7 (2.7)
PT (s)
X30
 
12.95 ± 7.29
12.66 ± 7.73
0.438
0.662
TT(s)
X31
 
18.28 ± 3.75
17.72 ± 1.58
2.206
0.028*
APTT(s)
X32
 
29.47 ± 6.76
30.20 ± 5.94
−1.300
0.194
FIB(g/L)
X33
 
2.84 ± 0.84
2.83 ± 0.89
0.131
0.896
FDP
X34
 
23.16 ± 28.85
5.28 ± 5.78
9.742
<0.001*
INR
X35
 
1.15 ± 1.23
1.09 ± 0.81
0.653
0.514
D-Dimer (mg/L)
X36
 
8.55 ± 14.37
1.37 ± 2.14
7.923
<0.001*
albumin (g/L)
X37
 
36.88 ± 5.05
37.01 ± 5.10
−0.290
0.772
Platelet (*109/L)
X38
 
193.57 ± 74.38
188.94 ± 81.93
0.671
0.503
WBC(*109/L)
X39
 
7.44 ± 2.81
6.42 ± 3.27
3.793
<0.001*
RBC(*109/L)
X40
 
4.43 ± 3.66
4.23 ± 0.64
0.863
0.389
Caprini score
X41
 
4.60 ± 2.72
3.56 ± 1.13
5.661
<0.001*
*Note: *Statistically significant at 0.05 leve

Multivariate analysis of VTE risk early warning indicators

Univariate analysis was performed on 41 variables, of which there were 15 variables with statistical significance of P < 0.05. In order not to omit possible VTE risk early warning related variables, increase the sensitivity of risk early warning model and allow more possible variables to be included in the variable, the variables with P < 0.3 in the univariate analysis or consistent with literature reports and clinical experience were included in the subsequent multivariate analysis. Therefore, we adopted a total of 28 variables. After colinear analysis, all variables had VIF less than 3, it can be considered no co-linearity among VTE risk warning indicators, which can be included in multi-factor logistic regression analysis, as shown in Table 2.
Table 2
Colinearity analysis of 28 VTE risk warning indicators including multivariate analysis
Variables
VIF
Variables
VIF
Gender
X1
1.406
Pleural effusion
X17
1.134
Patient source
X2
2.266
Unilateral lower limb pain
X18
1.205
Native place
X3
1.096
Local lower skin temperature increase
X22
1.062
Payment method
X4
1.123
Hypertension
X23
1.146
Length of stay (days)
X5
2.343
Diabetes
X24
1.113
Cough
X6
2.322
Smoking
X25
1.402
Expectorant
X7
2.302
Renal insufficiency
X27
1.054
Hemoptysis
X8
1.056
Liver disease
X28
1.065
Pleural chest pain
X10
1.122
TT(s)
X31
1.132
Cyanosis
X11
1.061
APTT(s)
X32
1.081
Anterior cardiac pain
X12
1.045
FDP
X34
1.767
Shortness of breath after exertion
X14
1.040
D-Dimer (mg/L)
X36
1.765
Chest tightness and shortness of breath
X15
1.148
WBC(*109/L)
X39
1.138
Unexplained syncope
X16
1.106
Caprini score
X41
1.143
The above 28 variables with P < 0.3 were included in Logistic regression analysis, and up to 7 independent risk warning indicators were screened out, namely pleural chest pain X10 (P < 0.001), shortness of breath after exercise X14 (P = 0.045), Chest tightness and shortness of breath X15 (P < 0.001), unilateral lower extremity pain X18 (P < 0.001), smoking X25 (P = 0.005), fibrinogen degradation product X34 (P < 0.001), Caprini score X41 (P = 0.004). The logistic regression was used to obtain regression coefficient, standard error, Wald chi-square value, P value, its corresponding OR value, and 95% confidence interval of the independent risk warning indicators, as shown in Table 3.
Table 3
Logistic regression parameter estimation of patients in VTE group and control group
Variables
Point estimation
Standard error
Wald chi-square values
P
OR value point estimation
Lower interval
Upper interval
X10
2.557
0.624
16.800
<0.001
12.893
3.797
43.784
X14
1.432
0.713
4.029
0.045
4.185
1.034
16.935
X15
2.977
0.420
50.344
<0.001
19.622
8.623
44.653
X18
3.445
0.882
15.274
<0.001
31.352
5.571
176.454
X25
1.086
0.384
8.023
0.005
2.963
1.397
6.284
X34
0.249
0.024
106.673
<0.001
1.282
1.223
1.344
X41
0.282
0.099
8.184
0.004
1.326
1.093
1.608

Construction of VTE risk warning model

According to above results The model independent variable assignment method was shown in Table 4. The final VTE risk warning model was as follows:
$$ \mathrm{p}={\mathrm{e}}^{\mathrm{x}}/\left(\ 1+{\mathrm{e}}^{\mathrm{x}}\ \right), $$
$$ \mathrm{x}=-4.840+2.557\bullet {\mathrm{X}}_{10(1)}+1.432\bullet {\mathrm{X}}_{14(1)}+2.977\bullet {\mathrm{X}}_{15(1)}+3.445\bullet {\mathrm{X}}_{18(1)}+1.086\bullet {\mathrm{X}}_{25(1)}+0.249\bullet {\mathrm{X}}_{34}+0.282\bullet {\mathrm{X}}_{41} $$
Table 4
The way to evaluate the value of the clinical variable of the VTE risk warning model
Clinical variables
No.
Assignment
Pleural chest pain
X10
No = 0, 1 = Yes
shortness of breath after fatigue
X14
No =0, 1 = Yes
chest dull shortness of breath
X15
No =0, 1 = Yes
unilateral lower limb pain
X18
No =0, 1 = Yes
smoking
X25
No =0, 1 = Yes
FDP
X34
Continuity variable
Caprini score
X41
Continuity variable
Outcome variables
Y
The control group =0, 1 = VTE group
Where e was the logarithm of natural numbers;
Pleural chest pain X10, shortness of breath after exercise X14, chest tightness and shortness of breath X15, unilateral lower extremity pain X18, smoking X25 and other variables were binary values (not specific medical history, 1 for yes, 0 for none). The unit of fibrinogen degradation product (X34) was (μg/ml). Caprini score (X41) was based on Caprini risk assessment scale, with no unit.

Evaluation and comparison of VTE risk warning model test efficacy

According to VTE risk warning model formula, the predicted probability of VTE occurrence was calculated by ROC curve analysis. The area under ROC curve (AUC) was 0.960 (95% CI: 0.940, 0.976), the standard error was 0.009, and Z = 52.279. The Hosmer-Lemeshow test (H-L test) was performed on the VTE risk warning model, and the χ2 was 55.441.
Caprini risk assessment scale and VTE risk warning model were used to predict the VTE truncation value (95% CI), which were 5 (4,5), 0.438 (0.263, 0.504), respectively. The VTE sensitivity was predicted to be 26.1 and 92.6% each, specificity 96.5 and 91.8%, accuracy 61.3 and 92.2%, and Youden index 0.23 and 0.84. AUC values were 0.596 (95%CI: 0.552, 0.638) and 0.960 (95%CI: 0.940, 0.976). The difference between above two groups was statistically significant (Z = 14.521, P < 0.0001), as shown in Fig. 1.

External validation of VTE risk warning model

The validation data set included 63 VTE patients and 85 non-VTE patients. There was no significant difference in the distribution of general clinical variables between validation data set and modeling data set (P > 0.05), which avoided the deviation of results due to uneven distribution of clinical variables.
The validation data set was substituted into the established VTE risk warning model formula to calculate the prediction probability of the occurrence of VTE in each patient, and the model truncation value was used to evaluate the efficiency prediction of validated data set. The sensitivity was 77.8%, specificity 84.7%, accuracy 81.8% and Youden index 0.625. It indicated that VTE risk warning model had a higher prediction efficiency both in the internal population and external population.

Discussion

VTE risk early warning model

In this study, multivariate logistic regression analysis was performed on general information, medical history data, blood parameters, and Caprini scores of 257 VTE patients to screen out VTE risk warning indicators other than Caprini assessment scale. A clinical diagnostic model was developed, including 4 medical history data, 2 laboratory data, and 1 scale score. The area under ROC curve (AUC) of this model was 0.960 (95%CI: 0.940, 0.976). A good disease risk prediction model was not just a simple mathematical combination of dependent and independent variables, but also had actual clinical importance behind it. Our original intention was to reach high prediction efficiency, differentiation ability and sensitivity of the prediction model. The most commonindicator evaluating the discriminability of prediction models was AUC, also known as the C statistic. The larger AUC, the better the discriminant ability of the prediction model. AUC < 0.6 indicates poor differentiation, 0.6–0.75 certain differentiation ability, and > 0.75 good differentiation ability. This research model showed high prediction efficiency for VTE (AUC = 0.960). In this study, a validation data set consisting of 63 cases of VTE patients and 85 cases of non-VTE patients was selected for model validation. The accuracy of VTE risk warning model for VTE prediction was 81.8%. The high AUC of this prediction model may be related to the modeling data of VTE group and control group matched 1: 1. Of course, the incidence of VTE was relatively low in the actual clinical process, which required continuous improvement and adjustment in a wider range of later use in order to reach clinical value maximization. The sensitivity of this model to VTE early warning was significantly higher than that of Caprini risk assessment scale. For VTEs in life-threatening situation, early identification will benefit the most. Therefore, the warning model’s high sensitivity was in line with expectations. Although the degree of sensitivity and specific it was often difficult to achieve perfect synchronization state of ideal, the early warning model of VTE specificity was 5% lower than Caprini risk assessment scale. It indicated that some of the non-VTE patients with risk factors were identified by some early warning indicators, leading to a certain amount of false positives.

Clinical status of VTE early warning mechanism

In order to take timely and effective measures to prevent the occurrence or further progress of VTE, clinicians and nurses should be kept informed of VTE early warning, including high risk of occurrence and early identification. There were many methods for clinical VTE evaluation, each with a certain scope of application and the results are barely satisfactory. A retrospective single-center study on patients who underwent thoracic surgery showed the areas under the receiver operating characteristic (ROC) curve of Caprini was 0.74 (P < 0.0001), Rogers 0.52 (P = 0.62), Padua 0.69 (P < 0.0001), and Khorana 0.64 (P = 0.0017), respectively [29]. In another study, ROC indicated that the Caprini score showed a significant but moderate relationship to VTE (AUC = 0.64; p = 0.004) [30]. Other studies had reached similar conclusion [3133]. Though, many embedded VTE warning software has been developed and integrated with electronic medical record system but such software was mostly based on Caprini Risk Assessment Scale, or Padua Assessment Scale, etc. [3336]. Vyas et al. [37] adopted the analysis way of Ishikawa Fishbone Diagram, and found that main reason for the improper prevention of DVT were the lacks of unified standard specifications, the computerized input system for doctors’ orders and effective risk assessment methods [38]. Also, others improved the Caprini Risk Assessment Scale [31, 32], but a lot of useful information in the electronic medical record system was not really used. These evaluation scales had not passed domestic large-scale clinical certification, and the accuracy and sensitivity of VTE screening were not very high. Therefore, the embedded automatic assessment and early warning system designed based on these scales usually have some inherent deficiencies.

Clinical significance of VTE early warning model

The prevention and treatment of VTE is a hot topic in the medical field, and it’s also a difficult point in clinical work. The VTE prediction model were established with purpose of making accurate assessment and diagnosis of VTE in the first time and avoiding adulterating human factors as much as possible. We know that there is a lot of VTE-related information in the electronic medical record system [27, 3335, 3941], and such information needs to be further explored and fully utilized in the clinical VTE warning. The VTE risk warning model made full use of Caprini risk assessment scale, which was widely used in clinical medicine and surgery, with the important clinical symptoms and signs of VTE patients and laboratory examination indicators, to carry out comprehensive and multi-dimensional warning and achieve higher prediction efficiency. The work intensity of Chinese medical staff is very high, and it’s a great challenge to monitor patients’ conditions consistently. We screened six independent warning indicators except the Caprini score, including pleural chest pain, shortness of breath after exercise, chest tightness and shortness of breath, unilateral lower extremity pain, smoking, fibrinogen degradation product. We set up standard terms and captured the records of standard terms in electronic medical record system in order to establish electronic active alarm system which can prompt doctors and nurses to take timely responses. It is of great clinical importance to develop embedded electronic VTE active alarm systems based on VTE risk warning model.

The deficiency and prospect of this research

We could not avoid the sample selectivity bias caused by the retrospective study. During this study, prothrombin time, D-dimer, and leukocytes in blood biochemical indicators were statistically important in univariate analysis, but they failed to enter the model during multivariate analysis. In addition, several articles had shown that platelets, inflammatory indicators, and the ratio of certain cell counts were also important in VTE early warning. Therefore, many blood biochemical indicators in clinical had potential value in the prediction and warning of VTE, which needs to be proved by more high-quality studies. This study only explored newly discovered independent warning indicators of VTE, and the mechanism of each warning indicator needs to be further studied. In addition, due to the limitation of various factors in the single-center study, the all-dimensional and multi-dimensional VTE risk warning model based on series of clinical comprehensive indicators needs to be constantly improved, verified and promoted in more centers and larger samples.

Conclusions

In this study, VTE risk warning model includes seven independent risk factors, namely pleural chest pain, shortness of breath after exercise, chest tightness and shortness of breath, unilateral lower extremity pain, smoking, fibrinogen degradation product, Caprini score. A high early warning effect has been verified on VTE in hospitalized patients and the VTE risk warning model has certain clinical application value.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12872-020-01519-9.

Acknowledgments

Not applicable.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anhänge

Supplementary information

Literatur
1.
Zurück zum Zitat Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–74.CrossRef Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–74.CrossRef
2.
Zurück zum Zitat Ma K, Wells P, Guzman C, Anderson D, Blostein M, Hirsch A, Lazo-Langner A, Kovacs MJ, Rodger M, Tagalakis V, Kahn SR. A multicenter prospective study of risk factors and treatment of unusual site thrombosis. Thromb Res. 2016;144:100–5.CrossRef Ma K, Wells P, Guzman C, Anderson D, Blostein M, Hirsch A, Lazo-Langner A, Kovacs MJ, Rodger M, Tagalakis V, Kahn SR. A multicenter prospective study of risk factors and treatment of unusual site thrombosis. Thromb Res. 2016;144:100–5.CrossRef
3.
Zurück zum Zitat Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. Heart disease and stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596.CrossRef Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. Heart disease and stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596.CrossRef
4.
Zurück zum Zitat Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med. 2011;171:831–7.PubMedPubMedCentral Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med. 2011;171:831–7.PubMedPubMedCentral
5.
Zurück zum Zitat Stein PD, Matta F, Hughes MJ. Home treatment of deep venous thrombosis according to comorbid conditions. Am J Med. 2016;129:392–7.CrossRef Stein PD, Matta F, Hughes MJ. Home treatment of deep venous thrombosis according to comorbid conditions. Am J Med. 2016;129:392–7.CrossRef
6.
Zurück zum Zitat Stein PD, Matta F, Hughes PG, Hourmouzis ZN, Hourmouzis NP, White RM, Ghiardi MM, Schwartz MA, Moore HL, Bach JA, et al. Home treatment of pulmonary embolism in the era of novel oral anticoagulants. Am J Med. 2016;129:974–7.CrossRef Stein PD, Matta F, Hughes PG, Hourmouzis ZN, Hourmouzis NP, White RM, Ghiardi MM, Schwartz MA, Moore HL, Bach JA, et al. Home treatment of pulmonary embolism in the era of novel oral anticoagulants. Am J Med. 2016;129:974–7.CrossRef
7.
Zurück zum Zitat Klil-Drori AJ, Coulombe J, Suissa S, Hirsch A, Tagalakis V. Temporal trends in outpatient management of incident pulmonary embolism and associated mortality. Thromb Res. 2018;161:111–6.CrossRef Klil-Drori AJ, Coulombe J, Suissa S, Hirsch A, Tagalakis V. Temporal trends in outpatient management of incident pulmonary embolism and associated mortality. Thromb Res. 2018;161:111–6.CrossRef
8.
Zurück zum Zitat White C, Noble SIR, Watson M, Swan F, Allgar VL, Napier E, Nelson A, McAuley J, Doherty J, Lee B, et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. Lancet Haematol. 2019;6(2):e79–88.CrossRef White C, Noble SIR, Watson M, Swan F, Allgar VL, Napier E, Nelson A, McAuley J, Doherty J, Lee B, et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. Lancet Haematol. 2019;6(2):e79–88.CrossRef
9.
Zurück zum Zitat Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol. 2005;95(12):1525–6.CrossRef Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol. 2005;95(12):1525–6.CrossRef
10.
Zurück zum Zitat Zhang J, Liu ZY. Practice of intervention in management of venous thromboembolism in hospital. Chin J Hosp Adm. 2017;33(1):51–3. Zhang J, Liu ZY. Practice of intervention in management of venous thromboembolism in hospital. Chin J Hosp Adm. 2017;33(1):51–3.
11.
Zurück zum Zitat Chinese Medical Association Committee for Prevention and Treatment of Thromboembolism. Construction of a hospital internal venous thromboembolism prevention and management system. Chin J Hosp Adm. 2013;29(1):28–31. Chinese Medical Association Committee for Prevention and Treatment of Thromboembolism. Construction of a hospital internal venous thromboembolism prevention and management system. Chin J Hosp Adm. 2013;29(1):28–31.
12.
Zurück zum Zitat Lung BE, Kanjiya S, Bisogno M, Komatsu DE, Wang ED. Risk factors for venous thromboembolism in total shoulder arthroplasty. JSES Open Access. 2019;3(3):183–8.CrossRef Lung BE, Kanjiya S, Bisogno M, Komatsu DE, Wang ED. Risk factors for venous thromboembolism in total shoulder arthroplasty. JSES Open Access. 2019;3(3):183–8.CrossRef
13.
Zurück zum Zitat Hereford T, Thrush C, Kimbrough MK. Using injury severity score and abbreviated injury score to determine venous thromboembolism risk. Cureus. 2019;11(10):e5977.PubMedPubMedCentral Hereford T, Thrush C, Kimbrough MK. Using injury severity score and abbreviated injury score to determine venous thromboembolism risk. Cureus. 2019;11(10):e5977.PubMedPubMedCentral
14.
Zurück zum Zitat Kaewborisutsakul A, Tunthanathip T, Yuwakosol P, Inkate S, Pattharachayakul S. Postoperative venous thromboembolism in Extramedullary spinal tumors. Asian J Neurosurg. 2020;15(1):51–8.CrossRef Kaewborisutsakul A, Tunthanathip T, Yuwakosol P, Inkate S, Pattharachayakul S. Postoperative venous thromboembolism in Extramedullary spinal tumors. Asian J Neurosurg. 2020;15(1):51–8.CrossRef
15.
Zurück zum Zitat Kunutsor SK, Barrett MC, Whitehouse MR, Blom AW. Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: meta-analyses of incidence, temporal trends and potential risk factors. Thromb Res. 2020;189:13–23.CrossRef Kunutsor SK, Barrett MC, Whitehouse MR, Blom AW. Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: meta-analyses of incidence, temporal trends and potential risk factors. Thromb Res. 2020;189:13–23.CrossRef
16.
Zurück zum Zitat Connolly GC, Francis CW. Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2013;2013:684–91.CrossRef Connolly GC, Francis CW. Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2013;2013:684–91.CrossRef
17.
Zurück zum Zitat Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–23.CrossRef Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–23.CrossRef
18.
Zurück zum Zitat Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219–30.CrossRef Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219–30.CrossRef
19.
Zurück zum Zitat Kang G, Zhang H. Risk factors for venous thromboembolism. Am J Med. 2019;132(11):e807.CrossRef Kang G, Zhang H. Risk factors for venous thromboembolism. Am J Med. 2019;132(11):e807.CrossRef
21.
Zurück zum Zitat Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin M, Haas M, Lindström S, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019;51(11):1574–9.CrossRef Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin M, Haas M, Lindström S, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019;51(11):1574–9.CrossRef
23.
24.
Zurück zum Zitat Wei WT, Liu PP, Lin SM, Peng CC, Wang JH, Huang HK, Loh CH. Hypothyroidism and the risk of venous thromboembolism: a Nationwide cohort study. Thromb Haemost. 2020;120(3):505–14.CrossRef Wei WT, Liu PP, Lin SM, Peng CC, Wang JH, Huang HK, Loh CH. Hypothyroidism and the risk of venous thromboembolism: a Nationwide cohort study. Thromb Haemost. 2020;120(3):505–14.CrossRef
26.
Zurück zum Zitat Abuduhalike R, Sun J, Zhao L, Mahemuti A. Correlation study of venous thromboembolism with SAA, IL-1, and TNF-a levels and gene polymorphisms in Chinese population. J Thorac Dis. 2019;11(12):5527–34.CrossRef Abuduhalike R, Sun J, Zhao L, Mahemuti A. Correlation study of venous thromboembolism with SAA, IL-1, and TNF-a levels and gene polymorphisms in Chinese population. J Thorac Dis. 2019;11(12):5527–34.CrossRef
27.
29.
Zurück zum Zitat Tian B, Li H, Cui S, Song C, Li T, Hu B. A novel risk assessment model for venous thromboembolism after major thoracic surgery: a Chinese single-center study. J Thorac Dis. 2019;11(5):1903–10.CrossRef Tian B, Li H, Cui S, Song C, Li T, Hu B. A novel risk assessment model for venous thromboembolism after major thoracic surgery: a Chinese single-center study. J Thorac Dis. 2019;11(5):1903–10.CrossRef
30.
Zurück zum Zitat Frankel J, Belanger M, Tortora J, McLaughlin T, Staff I, Wagner J. Caprini score and surgical times linked to the risk for venous thromboembolism after robotic-assisted radical prostatectomy. Turk J Urol. 2020;46(2):108–14.CrossRef Frankel J, Belanger M, Tortora J, McLaughlin T, Staff I, Wagner J. Caprini score and surgical times linked to the risk for venous thromboembolism after robotic-assisted radical prostatectomy. Turk J Urol. 2020;46(2):108–14.CrossRef
31.
Zurück zum Zitat Henke PK. Adding thrombodynamic assessment to Caprini risk assessment to improve venous thromboembolism risk specificity. J Vasc Surg Venous Lymphat Disord. 2020;8(1):42–3.CrossRef Henke PK. Adding thrombodynamic assessment to Caprini risk assessment to improve venous thromboembolism risk specificity. J Vasc Surg Venous Lymphat Disord. 2020;8(1):42–3.CrossRef
32.
Zurück zum Zitat Hanh BM, Cuong LQ, Son NT, Duc DT, Hung TT, Hung DD, Giang TB, Hiep NH, Xuyen HTH, Nga NT, et al. Determination of Risk Factors for Venous Thromboembolism by an Adapted Caprini Scoring System in Surgical Patients. J Pers Med. 2019;9(3). https://doi.org/10.3390/jpm9030036.CrossRef Hanh BM, Cuong LQ, Son NT, Duc DT, Hung TT, Hung DD, Giang TB, Hiep NH, Xuyen HTH, Nga NT, et al. Determination of Risk Factors for Venous Thromboembolism by an Adapted Caprini Scoring System in Surgical Patients. J Pers Med. 2019;9(3). https://​doi.​org/​10.​3390/​jpm9030036.CrossRef
33.
Zurück zum Zitat Yang Y, Wang X, Huang Y, Chen N, Shi J, Chen T. Ontology-based venous thromboembolism risk assessment model developing from medical records. BMC Med Inform Decis Mak. 2019;19(Suppl 4):151.CrossRef Yang Y, Wang X, Huang Y, Chen N, Shi J, Chen T. Ontology-based venous thromboembolism risk assessment model developing from medical records. BMC Med Inform Decis Mak. 2019;19(Suppl 4):151.CrossRef
34.
Zurück zum Zitat Zhao HL, Dai LY, Lv M, Shi YM, Zhang SX. Development of information-based nosocomial venous thromboembolism risk management system. J Nurs. 2018;25(24):9–12. Zhao HL, Dai LY, Lv M, Shi YM, Zhang SX. Development of information-based nosocomial venous thromboembolism risk management system. J Nurs. 2018;25(24):9–12.
35.
Zurück zum Zitat Owodunni OP, Haut ER, Shaffer DL, Hobson DB, Wang J, Yenokyan G, Kraus PS, Aboagye JK, Florecki KL, Webster KLW, et al. Using electronic health record system triggers to target delivery of a patient-centered intervention to improve venous thromboembolism prevention for hospitalized patients: is there a differential effect by race? PLoS One. 2020;15(1):e0227339.CrossRef Owodunni OP, Haut ER, Shaffer DL, Hobson DB, Wang J, Yenokyan G, Kraus PS, Aboagye JK, Florecki KL, Webster KLW, et al. Using electronic health record system triggers to target delivery of a patient-centered intervention to improve venous thromboembolism prevention for hospitalized patients: is there a differential effect by race? PLoS One. 2020;15(1):e0227339.CrossRef
36.
Zurück zum Zitat Ortel TL, Arnold K, Beckman M, Brown A, Reyes N, Saber I, Schulteis R, Singh BP, Sitlinger A, Thames EH. Design and implementation of a comprehensive surveillance system for venous thromboembolism in a defined region using electronic and manual approaches. Appl Clin Inform. 2019;10(3):552–62.CrossRef Ortel TL, Arnold K, Beckman M, Brown A, Reyes N, Saber I, Schulteis R, Singh BP, Sitlinger A, Thames EH. Design and implementation of a comprehensive surveillance system for venous thromboembolism in a defined region using electronic and manual approaches. Appl Clin Inform. 2019;10(3):552–62.CrossRef
37.
Zurück zum Zitat Vyas D, Bearelly D, Boshard B. A multidisciplinary quality improvement educational initiative to improve the rate of deep-vein thrombosis prophylaxis. lnt J Pharm Pract. 2014;22(1):92–5.CrossRef Vyas D, Bearelly D, Boshard B. A multidisciplinary quality improvement educational initiative to improve the rate of deep-vein thrombosis prophylaxis. lnt J Pharm Pract. 2014;22(1):92–5.CrossRef
38.
Zurück zum Zitat Xuan CX, Chen SM, Xie LL, Yang Y, Wang SW. Effect analysis of electronic simplified Caprini risk assessment in the prevention of deep venous thrombosis in ICU patients. J Bengbu Med Coll. 2018;43(3):394–6. Xuan CX, Chen SM, Xie LL, Yang Y, Wang SW. Effect analysis of electronic simplified Caprini risk assessment in the prevention of deep venous thrombosis in ICU patients. J Bengbu Med Coll. 2018;43(3):394–6.
40.
Zurück zum Zitat Avnery O, Martin M, Bura-Riviere A, Barillari G, Mazzolai L, Mahé I, Marchena PJ, Verhamme P, Monreal M. Ellis MH; RIETE investigators. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med. 2020;287(1):32–41.CrossRef Avnery O, Martin M, Bura-Riviere A, Barillari G, Mazzolai L, Mahé I, Marchena PJ, Verhamme P, Monreal M. Ellis MH; RIETE investigators. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med. 2020;287(1):32–41.CrossRef
41.
Zurück zum Zitat Kunutsor SK, Mäkikallio TH, Kauhanen J, Voutilainen A, Laukkanen JA. Lipoprotein(a) is not associated with venous thromboembolism risk. Scand Cardiovasc J. 2019;53(3):125–32.CrossRef Kunutsor SK, Mäkikallio TH, Kauhanen J, Voutilainen A, Laukkanen JA. Lipoprotein(a) is not associated with venous thromboembolism risk. Scand Cardiovasc J. 2019;53(3):125–32.CrossRef
Metadaten
Titel
Predicting the occurrence of venous thromboembolism: construction and verification of risk warning model
verfasst von
Chen Shen
Binqian Ge
Xiaoqin Liu
Hao Chen
Yi Qin
Hongwu Shen
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2020
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01519-9

Weitere Artikel der Ausgabe 1/2020

BMC Cardiovascular Disorders 1/2020 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.